parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia
PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Drug Information

Indication: Patients w/ moderate to severe Alzheimer's disease.

Indication: Parkinson's disease either as monotherapy or combined w/ dopatherapy from the outset or secondarily.

Indication: Mild, moderate & severe Alzheimer's dementia.

Indication: Parkinson's disease. Menstrual disorders & infertility. Benign breast disease. Prolactinoma. Acromegaly.

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa. ...

Indication: Signs & symptoms of advanced idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa.

Indication: Relief of muscular conditions, tension headache, non-articular rheumatism & dysmenorrhoea.

Indication: Mild, moderate & severe Alzheimer's dementia.

Indication: Adjunct to l-dopa/benserazide or l-dopa/carbidopa in patients w/ Parkinson's disease & end-of-dose motor f...

Indication: Mild to moderately severe dementia associated w/ Alzheimer's or Parkinson's disease & severe dementia asso...

1  /  4
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 23 Mar 2020

Prompt treatment with tranexamic acid may reduce intracerebral haemorrhage (ICH) growth in patients with ongoing bleeding, though the timing of treatment appears to be key to improved outcomes, according to a study presented at ISC 2020.